| 高雄醫學大學 |
2007 |
Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C
|
黃志富;余明隆;戴嘉言;張文宇;莊萬龍 |
| 高雄醫學大學 |
2007 |
CLINICAL EVALUATION OF THE ABBOTT REAL-TIME PCR ASSAY FOR QUANTIFICATION OF HEPATITIS C VIRUS INFECTION AMONG GENOTYPE-1 AND -2 PATIENTS IN TAIWAN- COMPARISON TO THE VERSANT HCV RNA 3.0 ASSAY
|
戴嘉言;黃志富;余明隆;莊萬龍;張文宇 |
| 高雄醫學大學 |
2007 |
High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 wks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): Prospective, randomized, controlled study comparing 24 & 48 wks of treatm
|
余明隆;戴嘉言;黃志富;李立柏;謝明彥;丘長富;侯乃仁;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍* |
| 高雄醫學大學 |
2007 |
PHARMACOGENOMICS STUDY FOR 24 VS. 48 WEEKS TREATMENT OF PEGINTERFERON PLUS RIBAVIRIN FOR GENOTYPE 1b CHRONIC HEPATITIS C
|
戴嘉言;黃志富;謝明彥;陳信成;余明隆;莊萬龍 |
| 高雄醫學大學 |
2007 |
RELATIONSHIP BETWEEN GLUCOSE ABNORMALITIES AND RESPONSE TO PEGYLATED INTERFERON ALFA PLUS RIBAVIRIN COMBINATION THERAPY IN CHRONIC HEPATITIS C PATIENTS
|
謝明彥;戴嘉言;黃志富;林子堯;余明隆;莊萬龍 |
| 高雄醫學大學 |
2007 |
PRETREATMENT INSULIN RESISTANCE WAS ASSOCIATED WITH RESPONSE TO COMBINATION THERAPY WITH PEGYLATED INTERFERON ALFA AND RIBAVIRIN IN NON-DIABETIC PATIENTS WITH CHRONIC HEPATITIS C
|
余明隆;戴嘉言;黃志富;李立柏;王良彥;莊萬龍 |
| 高雄醫學大學 |
2007 |
葡萄糖異常與慢性C型肝炎患者接受長效型干擾素（pegylated interferon alfa）合併ribavirin治療反應之關聯性研究
|
謝明彥;戴嘉言;李立柏;余明隆;王良彥;莊萬龍;張文宇 |
| 高雄醫學大學 |
2007 |
Underestimation of glucose abnormalities among patients with chronic hepatitis C infection
|
黃志富;余明隆;戴嘉言;辛錫璋;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
血清中adiponectin濃度在膽囊之膽固醇結石和色素石間之變化
|
王森稔;葉耀宗;余明隆;王肇齡;李金德 ; Wang SN;Yeh YT;Yu ML;Wang CL;Lee KT |
| 高雄醫學大學 |
2006 |
Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
|
林子堯;莊萬龍;莊豔凰;余明隆;謝明裕;王良彥;蔡榮發 ; Zu-Yau Lin;Wan-Long Chuang;Yen-Huang Chuang;Ming-Lung Yu;Ming-Yuh Hsieh;Liang-Yen Wang;Jung-Fa Tsai |
| 高雄醫學大學 |
2006 |
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
|
余明隆;林錫銘;李全謨;戴嘉言;張文宇;陳信成;李立柏;林子堯;謝明裕;王良彥;莊萬龍;廖運範 ; Yu ML;Lin SM;Lee CM;Dai CY;Chang WY;Chen SC;Lee LP;Lin ZY;Hsieh MY;Wang LY;Chuang WL;Liaw YF |
| 高雄醫學大學 |
2006 |
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide; multicentre study in Taiwan.
|
余明隆;林錫明;莊萬龍;戴嘉言;王景弘;盧勝男;沈一嫻;張文宇;李全謀;廖運範 ; Yu ML;Lin SM;Chuang WL;Dai CY;Wang JH;Lu SN;Sheen IS;Chang WY;Lee CM;Liaw YF |
| 高雄醫學大學 |
2006 |
Genetic predisposition of responsiveness to therapy for chronic hepatitis C.
|
黃渝棋;陳奕雄;顧之杰;莊萬龍;余明隆;賴明陽;趙有誠;李全謨;王景弘;戴嘉言;貝先芝;廖雅堂;陳培哲;陳定信 ; Hwang Y;Chen EY;Gu ZJ;Wan-Long Chuang;Ming-Lung Yu;Lai MY;Chao YC;Lee CM;Wang JH;Chia-Yen Dai;Shian-Jy Bey M;Liao YT;Chen PJ;Chen DS. |
| 高雄醫學大學 |
2006 |
Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
|
余明隆;戴嘉言;李立柏;謝明彥;侯乃仁;黃志富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 ; Yu ML;Dai CY;Lee LP;Hsieh MY;Hou NJ;Huang JF;Lin ZY;Chen SC;Hsieh MY;Wang LY;Chang WY;Chuang WL |
| 高雄醫學大學 |
2006 |
The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
|
黃志富;莊萬龍;戴嘉言;陳信成;林子堯;李立柏;王良彥;謝明裕;張文宇;余明隆 ; Jee-Fu Huang;Wan-Long Chuang;Chia-Yen Dai;Shinn-Cherng Chen;Zu-Yau Lin;Li-Po Lee;Liang-Yen Wang;Ming-Yuh Hsieh;Wen-Yu Chang;Ming-Lung Yu |
| 高雄醫學大學 |
2006 |
Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;黃志富;謝明裕;王良彥;余明隆 ; Dai CY;Chuang WL;Chang WY;Chen SC;Lee LP;Hsieh MY;Hou NJ;Lin ZY;Huang JF;Hsieh MY;Wang LY;Yu ML |
| 高雄醫學大學 |
2006 |
Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?
|
黃志富;莊萬龍;戴嘉言;何啟功;黃尚志;陳信成;林子堯;王良彥;張文宇; , 余明隆; Huang, JF;Chuang, WL;Dai, CY;Ho, CK;Hwang, SJ;Chen, SC;Lin, ZY;Wang, LY;Chang, WY; , Yu ML |
| 高雄醫學大學 |
2006 |
HEPATITIS C VIREMIA INCREASES PREVALENCE OF NON-INSULIN-DEPENDENT DIABETES MELLITUS IN A HEPATITIS B AND C ENDEMIC AREA
|
黃志富;莊萬龍;戴嘉言;何啟功;張文宇;余明隆 |
| 高雄醫學大學 |
2006 |
膽固醇主動輸出蛋白質(ABCG 5/8)的基因多型性變化和血脂肪之相關性
|
王巧伶;蕭璧容;謝翠娟;余明隆;辛錫璋 |
| 高雄醫學大學 |
2006 |
A simple noninvasive index for predicting long-term outcome of chronic hepatitis c after interferon-based therapy
|
余明隆;Dal, CY;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
A randomized study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C
|
余明隆;戴嘉言;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2006 |
CLINICAL SIGNIFICANCE OF ERYTHROPOIETIN IN CHRONIC HEPATITIS C PATIENTS
|
侯乃仁;余明隆;戴嘉言;林子堯;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
A randomized, controlled, open-label study of peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 vs. 24 weeks in patients with genotype 2 hepatitis C infection
|
余明隆;黃志富;侯乃仁;李立柏;謝明彥;丘長富;林子堯;陳信成;謝明彥;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Underestimation of glucose abnormalities among patients with chronic hepatitis C infection
|
黃志富;余明隆;戴嘉言;辛錫璋;張文宇;莊萬龍 |
| 高雄醫學大學 |
2006 |
Predictors for early mortality in lamivudine-treated patients with chronic hepatitis B-related decompensation in Taiwan ”has been accepted for poster presentation at the forthcoming.
|
戴嘉言;莊萬龍;李立柏;謝明裕;侯乃仁;陳信成;林子堯;謝明彥;王良彥;黃志富;張文宇;余明隆 |
| 高雄醫學大學 |
2005 |
Safety of fine-needle aspiration in patients with small hepatocellular carcinoma.
|
王志文;林子堯;莊萬龍;王良彥;余明隆;陳信成;謝明裕;蔡榮發;張文宇 ; Wang CW;Lin ZY;Chuang WL;Wang LY;Yu ML;Chen SC;Hsieh MY;Tsai JF;Chang WY. |
| 高雄醫學大學 |
2005 |
Serum insulin-like growth factor-II as a serologic marker of small hepatocellular carcinoma
|
蔡榮發;鄭貞英;莊麗月;尤慧玲;王良彥;謝明裕;陳信成;莊萬龍;林子堯;余明隆;戴嘉言 ; Tsai JF;Jeng JE;Chuang LY;You HL;Wang LY;Hsieh MY;Chen SC;Chuang WL;Lin ZY;Yu ML;Dai CY |
| 高雄醫學大學 |
2005 |
Tumor necrosis factor alpha promoter polymorphism at position-308 predicts hepatitis C virus response to combination therapy with high dose interferon and ribavirin
|
戴嘉言;余明隆;莊萬龍;李立柏;謝明裕;侯乃仁;張文宇 ; Dai CY;Yu ML;Chuang WL;Lee LP;Hsieh MY;Hou NJ;Chang WY |
| 高雄醫學大學 |
2005 |
在台灣B型肝炎疫苗注射20年後之B型肝炎表面抗原陽性之盛行率
|
林文一;余明隆;楊正福;邱昭景;何啟功;莊萬龍;張文宇 |
| 高雄醫學大學 |
2005 |
非酒精性脂肪肝病人容易合併前期糖尿病
|
蕭璧容;陸宏銘;余明隆;林文一;辛錫璋 |
| 高雄醫學大學 |
2005 |
第二型類胰島素生長因子做為小型肝細胞癌血清學標誌之研究
|
蔡榮發;王良彥;莊萬龍;林子堯;余明隆;戴嘉言 |
| 高雄醫學大學 |
2005 |
長效型干擾素合併Rivbavirin治療感染基因型1b之慢性C型肝炎病患：24及48週療程之比較
|
余明隆;戴嘉言;陳信成;莊萬龍;王良彥;張文宇 |
| 高雄醫學大學 |
2005 |
甲型腫瘤壞死因子促動基因多型性與慢性C型肝炎患者以甲型干擾素及ribavirin合併治療療效相關性研究
|
戴嘉言;余明隆;李立柏;王良彥;莊萬龍 |
| 高雄醫學大學 |
2005 |
慢性C型肝炎患者臨床表徵及以甲型干擾素及ribavirin合併治療療效與丙型干擾素基因多型性基因多型性相關性
|
謝明彥;戴嘉言;余明隆;李立柏;莊萬龍 |
| 高雄醫學大學 |
2005 |
Interferon-alpha could reduce the occurrence of liver cirrhosis and hepatocellular carcinoma for naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
|
莊萬龍;余明隆;戴嘉言;陳信成;李立柏;謝明彥;林子堯;謝明裕;王良彥;蔡榮發;黃志富 |
| 高雄醫學大學 |
2005 |
DIAGNOSIS OF ICTERIC TYPE HEPATOCELLULAR CARCINOMA BY FINE NEEDLE ASPIRATION CYTOLOGY
|
余明隆;黃志富;陳信成;王良彥;戴嘉言;莊萬龍;張文宇 |
| 高雄醫學大學 |
2005 |
Interferon-Based Therapy in Chronic Hepatitis C Reduces Cirrhosis and Hepatocellular Carcinoma and Improves Survival: A Nation-Wide, Multicenter Study in Taiwan
|
余明隆;廖運範;莊萬龍;林錫銘;戴嘉言;張文宇;李詮謀 |
| 高雄醫學大學 |
2005 |
FN-BASED THERAPY IN CHRONIC HEPATITIS C REDUCES LC AND HEPATOCELLULAR CARCINOMA AND IMPROVES SURVIVAL: A NATION-WIDE, MULTICENTER STUDY IN TAIWAN
|
余明隆;廖運範;莊萬龍;林錫銘;戴嘉言;李詮模 |
| 高雄醫學大學 |
2005 |
A randomized trial of 24-week versus 48-week courses of peginterferon alpha-2b plus ribavirin for genotype-1b infected chronic hepatitis C patients: a pilot study in Taiwan
|
余明隆;戴嘉言;林子堯;李立柏;謝明彥;陳信成;謝明裕;王良彥;張文宇;莊萬龍 |
| 高雄醫學大學 |
2005 |
干擾素治療慢性C型肝炎對於肝硬化、肝癌之發生及病患存活之影響: 台灣多中心研究
|
余明隆;廖運範;莊萬龍;林錫銘;戴嘉言;張文宇;李全謀 |
| 高雄醫學大學 |
2005 |
慢性 C 型肝炎治療的新進展
|
莊萬龍;余明隆;戴嘉言;張文宇 |
| 高雄醫學大學 |
2005 |
小型肝細胞癌血清第二型類胰島素生長因子之研究
|
蔡榮發;王良彥;謝明裕;陳信成;莊萬龍;林子堯;余明隆;戴嘉言;謝明彥;李立柏 |
| 高雄醫學大學 |
2005 |
甲型腫瘤壞死因子促動基因–308基因多型性與高劑量甲型干擾素合併ribavirin治療慢性C型肝炎療效之關聯
|
戴嘉言;余明隆;.莊萬龍;李立柏;謝明彥;侯乃仁;林子堯;陳信成;謝明裕;王良彥;蔡榮發;王良彥;蔡榮發;張文宇 |
| 高雄醫學大學 |
2005 |
感染基因型第二型之慢性C型肝炎病患以長效型干擾素合併Rivbavirin治療16及24週療程之比較:期中分析
|
戴嘉言;余明隆;李立柏;謝明彥;侯乃仁;黃志富;丘長富;林子堯;陳信成;謝明裕;王良彥;莊萬龍;張文宇 |
| 高雄醫學大學 |
2005 |
Polymorphisms in the Interferon-gamma gene at position +874 in patients with chronic Hepatitis C treated with high dose Interferon-Alpha and Ribavirin
|
戴嘉言;莊萬龍;張文宇;陳信成;李立柏;謝明彥;侯乃仁;林子堯;謝明裕;王良彥;余明隆 |
| 高雄醫學大學 |
2005 |
THE POLYMORPHISM OF EIF-2α GENE REGULATORY REGION 2 AND CLINICAL FEATURE OFCHRONIC HEPATITIS C AND RESPONSE TO COMBINATION THERAPY WITH HIGH DOSE INTERFERON AND RIBAVIRINTION
|
戴嘉言;余明隆;李立柏;謝明彥;莊萬龍;張文宇 |
| 高雄醫學大學 |
2005 |
Tumor necrosis factor alpha promoter polymorphisms at position –308 predict hepatitis C virus response to combination therapy with high dose interferon and ribavirin
|
戴嘉言;余明隆;莊萬龍;李立柏;謝明彥;侯乃仁;王良彥;張文宇 |
| 高雄醫學大學 |
2004 |
檳榔是肝硬化病人併發肝癌的危險因子
|
蔡榮發;鄭貞英;莊麗月;林子堯;謝明裕;陳信成;莊萬龍;王良彥;余明隆;戴嘉言 ; Tsai JF;Jeng JE;Chuang LY;Ho MS;Ko YC;Lin ZY;Hsieh MY;Chen SC;Chuang WL;Wang LY;Yu ML;Dai CY |
| 高雄醫學大學 |
2004 |
A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors
|
余明隆;戴嘉言;陳信成;李立柏;黃志富;林子堯;謝明裕;王良彥;莊萬龍;張文宇 ; Ming-Lung Yu;Chia-Yen Dai;Shinn-Cherng Chen;Li-Po Lee;Jee-Fu Huang;Zu-Yau Lin;Ming-Yuh Hsieh;Liang-Yen Wang;Wan-Long Chuang;Wen-Yu Chang |
